Aclaris Therapeutics (ACRS) Operating Expenses (2014 - 2026)

Aclaris Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $24.2 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 23.79% year-over-year to $24.2 million; the TTM figure through Mar 2026 stood at $88.8 million (down 44.07% YoY), while the FY2025 annual figure was $84.2 million, down 47.59% from the prior year.
• Operating Expenses was $24.2 million for Q1 2026 at Aclaris Therapeutics, up from $24.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $108.9 million in Q4 2024 to a low of $14.8 million in Q3 2024.
• Historically, Operating Expenses has averaged $30.4 million across 5 years, with a median of $22.5 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 403.71% in 2024, then sank 77.93% in 2025.
• A 5-year view of Operating Expenses shows it stood at $36.8 million in 2022, then slumped by 41.31% to $21.6 million in 2023, then soared by 403.71% to $108.9 million in 2024, then tumbled by 77.93% to $24.0 million in 2025, then rose by 0.66% to $24.2 million in 2026.
• The last three Operating Expenses figures came in at $24.2 million (Q1 2026), $24.0 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.